Dan Cojocari
Dan Cojocari
Email verificata su abbvie.com - Home page
Titolo
Citata da
Citata da
Anno
Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium
EO Pettersen, P Ebbesen, RG Gieling, KJ Williams, L Dubois, P Lambin, ...
Journal of enzyme inhibition and medicinal chemistry 30 (5), 689-721, 2015
982015
A three-dimensional engineered tumour for spatial snapshot analysis of cell metabolism and phenotype in hypoxic gradients
D Rodenhizer, E Gaude, D Cojocari, R Mahadevan, C Frezza, ...
Nature materials 15 (2), 227-234, 2016
962016
AMPK regulates metabolism and survival in response to ionizing radiation
VE Zannella, D Cojocari, S Hilgendorf, RN Vellanki, S Chung, ...
Radiotherapy and Oncology 99 (3), 293-299, 2011
572011
PTP1B controls non-mitochondrial oxygen consumption by regulating RNF213 to promote tumour survival during hypoxia
RS Banh, C Iorio, R Marcotte, Y Xu, D Cojocari, AA Rahman, J Pawling, ...
Nature cell biology 18 (7), 803-813, 2016
502016
The autophagy associated gene, ULK1, promotes tolerance to chronic and acute hypoxia
MBE Schaaf, D Cojocari, TG Keulers, B Jutten, MH Starmans, MC de Jong, ...
Radiotherapy and Oncology 108 (3), 529-534, 2013
482013
New small molecule inhibitors of UPR activation demonstrate that PERK, but not IRE1α signaling is essential for promoting adaptation and survival to hypoxia
D Cojocari, RN Vellanki, B Sit, D Uehling, M Koritzinsky, BG Wouters
Radiotherapy and Oncology 108 (3), 541-547, 2013
452013
5-Azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis
S Jin, D Cojocari, JJ Purkal, R Popovic, NN Talaty, Y Xiao, LR Solomon, ...
Clinical Cancer Research 26 (13), 3371-3383, 2020
202020
Combination of enasidenib and venetoclax shows superior anti-leukemic activity against IDH2 mutated AML in patient-derived xenograft models
S Cathelin, D Sharon, A Subedi, D Cojocari, DC Phillips, JD Leverson, ...
Blood 132 (Supplement 1), 562-562, 2018
172018
Hematologic tumor cell resistance to the BCL-2 inhibitor venetoclax: a product of its microenvironment?
JD Leverson, D Cojocari
Frontiers in oncology 8, 458, 2018
152018
Development of TRACER: tissue roll for analysis of cellular environment and response
D Rodenhizer, D Cojocari, BG Wouters, AP McGuigan
Biofabrication 8 (4), 045008, 2016
152016
Quantitative visualization of hypoxia and proliferation gradients within histological tissue sections
M Zaidi, F Fu, D Cojocari, TD McKee, BG Wouters
Frontiers in bioengineering and biotechnology 7, 397, 2019
92019
A three-dimensional engineered heterogeneous tumor model for assessing cellular environment and response
D Rodenhizer, T Dean, B Xu, D Cojocari, AP McGuigan
Nature protocols 13 (9), 1917-1957, 2018
92018
Pevonedistat, a Nedd-8 activating enzyme inhibitor, upregulates NOXA to increase effectiveness of azacitidine and venetoclax in preclinical models of acute myelogenous leukemia
BN Smith, D Cojocari, JJ Purkal, M Arrate, HE Ramsey, JD Leverson, ...
Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …, 2019
22019
Oxygen metabolism and hypoxia tolerance in organoid models of pancreatic ductal adenocarcinoma
J Zhang, Q Liu, D Cojocari, M Zaidi, T McKee, N Radulovich, MS Tsao, ...
Cancer Research 78 (13 Supplement), 2443-2443, 2018
22018
Therapeutic targeting of tumour hypoxia through the unfolded protein response and autophagy pathways
D Cojocari
12017
Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia
D Cojocari, BN Smith, JJ Purkal, MP Arrate, JD Huska, Y Xiao, A Gorska, ...
Haematologica, 2020
2020
5-Azacytidine Induces NOXA and PUMA Expression to Prime AML Cells for Venetoclax-Mediated Apoptosis
D Cojocari, S Jin, JJ Purkal, R Popovic, NN Talaty, Y Xiao, LR Solomon, ...
Blood 132 (Supplement 1), 2644-2644, 2018
2018
SP-0337: Understanding and targeting the underlying drivers of tumor hypoxia
B Wouters, D Cojocari, J Zhang, T McKee, M Zaidi, M Koritzinksy
Radiotherapy and Oncology 127, S178, 2018
2018
TRACER: a 3D engineered tumour for mapping cell metabolism and phenotype in heterogeneous microenvironments
D Rodenhizer, E Gaude, D Cojocari, R Mahadevan, C Frezza, ...
Front. Bioeng. Biotechnol. Conference Abstract: 10th World Biomaterials …, 2016
2016
PTP1B regulates the Moyamoya disease-associated E3 ligase, RNF213 and cellular dioxygenase activity to allow breast tumor survival in hypoxia
RS Banh, C Iorio, R Marcotte, Y Xu, D Cojocari, AA Rahman, J Pawling, ...
CANCER RESEARCH 75, 2015
2015
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20